BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25374410)

  • 21. [A case of chronic myeloid leukemia following TS-1 therapy for advanced gastric cancer].
    Higuchi M; Nishinaka H; Yamano Y
    Gan To Kagaku Ryoho; 2006 Dec; 33(13):2049-52. PubMed ID: 17197751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group.
    Sugimachi K; Maehara Y; Horikoshi N; Shimada Y; Sakata Y; Mitachi Y; Taguchi T
    Oncology; 1999 Oct; 57(3):202-10. PubMed ID: 10545788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.
    Takechi T; Nakano K; Uchida J; Mita A; Toko K; Takeda S; Unemi N; Shirasaka T
    Cancer Chemother Pharmacol; 1997; 39(3):205-11. PubMed ID: 8996521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
    Aichberger KJ; Herndlhofer S; Agis H; Sperr WR; Esterbauer H; Rabitsch W; Knöbl P; Haas OA; Thalhammer R; Schwarzinger I; Sillaber C; Jäger U; Valent P
    Eur J Clin Invest; 2007 Oct; 37(10):808-13. PubMed ID: 17727673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1.
    Tsuruoka Y; Kamano T; Kitajima M; Kawai K; Watabe S; Ochiai T; Sakamoto K; Shirasaka T
    Anticancer Drugs; 2006 Apr; 17(4):393-9. PubMed ID: 16549996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy].
    Kabashima A; Kitagawa D; Nakamura T; Kondo N; Teramoto S; Saito G; Funahashi T; Adachi E; Ikeda Y
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):1716-8. PubMed ID: 25731306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients.
    Yasui H; Kawakami T; Kashiwagi H; Mori K; Omae K; Kasai J; Yoshisue K; Kawahira M; Tsushima T; Machida N; Fukutomi A; Yamaguchi K
    Int J Clin Oncol; 2019 Jun; 24(6):660-665. PubMed ID: 31011915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outpatient oral chemotherapy with S-1 for unresectable or distant metastatic head and neck cancer.
    Maeda M; Yamashita T; Matsunobu T; Araki K; Tomifuji M; Shiotani A
    Anticancer Res; 2013 Aug; 33(8):3285-9. PubMed ID: 23898093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
    Shirasaka T; Nakano K; Takechi T; Satake H; Uchida J; Fujioka A; Saito H; Okabe H; Oyama K; Takeda S; Unemi N; Fukushima M
    Cancer Res; 1996 Jun; 56(11):2602-6. PubMed ID: 8653704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
    Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
    Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
    Shirasaka T; Taguchi T
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():4-18. PubMed ID: 16897967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
    Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
    Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.
    Klamova H; Faber E; Zackova D; Markova M; Voglova J; Cmunt E; Novakova L; Machova-Polakova K; Moravcova J; Dvorakova D; Michalova K; Brezinova J; Oltova A; Jarosova M; Cetkovsky P; Indrak K; Mayer J
    Neoplasma; 2010; 57(4):355-9. PubMed ID: 20429627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The efficacy of S-1 monotherapy as a 2nd/3rd-line therapy for unresectable recurrent colon cancer: Kanagawa conference of clinical oncology (KCCO)].
    Yokoyama T; Tokuhara H; Egawa T; Hashimoto O; Seki H; Koyanagi K; Bessho T
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1667-70. PubMed ID: 19838025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
    van Groeningen CJ; Peters GJ; Schornagel JH; Gall H; Noordhuis P; de Vries MJ; Turner SL; Swart MS; Pinedo HM; Hanauske AR; Giaccone G
    J Clin Oncol; 2000 Jul; 18(14):2772-9. PubMed ID: 10894878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer.
    Shiroyama T; Kijima T; Komuta K; Yamamoto S; Minami S; Ogata Y; Okafuji K; Imamura F; Hirashima T; Tachibana I; Kawase I; Kumanogoh A
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):783-9. PubMed ID: 22960985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
    Tyler T
    Ann Pharmacother; 2009 May; 43(5):920-7. PubMed ID: 19336654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Successful low-dose TS-1 administration in an elderly colon cancer patient with liver metastasis].
    Ohnishi T; Kanoh T; Kimura Y; Iwazawa T; Tono T; Nakano Y; Yano K; Monden T
    Gan To Kagaku Ryoho; 2007 Apr; 34(4):623-5. PubMed ID: 17431353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.